NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Eventually when all possibilities of raising cash are extinguished, we'll likely learn LTS had everything to do with the patient's unique system and less with any one kind of vaccine. All started with that decade plus old trial criteria.


However, there is no universal characteristic feature that can explain the entire group of GBM LTS as of now. A new approach that has not been tried to investigate the topic is expected to unveil the secret explaining the unique group of GBM LTS.

https://academic.oup.com/noa/article/2/1/vdz056/5684905


DCVAX trial 2018:
The surprising part was that the 100 ‘extended survivors’ don’t appear to have the usual characteristics associated with a good prognosis. We are continuing to study these patients to understand why they have done so well.”